Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 75
Selected: 0
NCT IDTitle
NCT06171139Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT01417182Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
NCT05327465Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
NCT01703065Cabozantinib in Men With Castration-Resistant Prostate Cancer
NCT03276572Phase I Trial of 225Ac-J591 in Patients With mCRPC
NCT00953576Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
NCT06040125Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
NCT07050433COMPASS Study for Metastatic Castration-resistant Prostate Cancer
NCT03532217Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
NCT05918263Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
NCT01961713Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
NCT03805594177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04090528pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT06449664Training for Men Undergoing Androgen Deprivation Therapy.
NCT03477864Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
NCT02856100Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
NCT02677376Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
NCT06200974Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
NCT06616597Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
NCT01950143Effect of Sulforaphane on Prostate CAncer PrEvention
NCT0471672568Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
NCT02269982Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
NCT06424275Prostate Cancer Awareness and Initiative for Screening in the European Union
NCT03957252Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
NCT00651222Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
NCT02080650Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
NCT02478125Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
NCT01379742Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT02025413Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
NCT04116775Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT02499835Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
NCT00744549Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
NCT05435495Mechanisms of Resistance to PSMA Radioligand Therapy
NCT06126731Combination Study of Antibiotics With Enzalutamide (PROMIZE)
NCT02735252PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
NCT05150236EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
NCT01289067Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca
NCT00156884A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
NCT05702619Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
NCT05355727PROSAIC-DS Study (PROState AI in Cancer - Decision Support)
NCT07002320Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
NCT04343885In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
NCT06305598Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
NCT03644303Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
NCT02582697Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT02300324The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS)
NCT06046040TmPSMA-02 in mCRPC
NCT05041504A Web-based Peer Navigation Program for Men With Prostate Cancer
NCT04430192Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
NCT02135484Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases